Navigation Links
Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Date:9/19/2007

Novel Antibiotic Candidate Rapidly Bactericidal Against Both Cultures and

Spores of the Anaerobic Bacterium Using Multiple in Vitro Methods

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released data from two studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against Clostridium difficile bacteria. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL.

C. difficile are anaerobic, gram-positive, spore-forming bacteria that are a major cause of morbidity in the hospitalized elderly. C. difficile infection is associated with many diseases, the most significant of which are uncomplicated diarrhea and pseudomembranous colitis, or severe infection of the colon. Often, after normal gut flora are eradicated by the use of antibiotics, it is postulated that C. difficile spores refractory to current antimicrobial therapies persist, causing recurrent infections. The U.S. Centers for Disease Control and Prevention (CDC) reports that each year nearly 10 percent of all hospitalized patients, or two million patients, contract C. difficile infections during their stay.

In the first study, presented as a poster entitled "In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin," researchers tested the activity of oritavancin versus the standards of care, metronidazole and vancomycin, against 33 genotypically distinct strains of C. difficile bacteria. Overall, in this study, oritavancin was more active than either metronidazole or vancomycin, and oritavancin was more active than vancomycin against 94% of the C. difficile strains tested by the broth macrodilution method.

In the second study, accepted as a late-breaker poster presentation entitled "Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic Clostridium difficile Spores," researchers compared the activity of oritavancin, metronidazole and vancomycin against epidemic C. difficile spores using spiral gradient endpoint, agar-based culture, and phase contrast microscopy. Using these three different experimental methods, results from the study indicated that oritavancin interacts with and disrupts the transition from dormant C. difficile spores to vegetative cells to a greater extent than existing therapeutic antimicrobial agents. In addition, there was a marked difference in oritavancin activity against C. difficile spores versus vegetative cells (5- to 13-fold lower MICs against the spores); Targanta believes that such a phenomenon has not been reported previously.

About Oritavancin

Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic candidate with potent bactericidal (killing) activity against a broad spectrum of gram-positive bacteria. The product candidate has been tested in over 1500 patients and has completed two Phase 3 studies for the treatment of complicated skin and skin structure infections (cSSSI) in which the primary endpoints were met. Targanta believes oritavancin's properties may give it distinct advantages over currently marketed therapies and expects to submit a New Drug Application to the U.S. Food and Drug Administration in the first quarter of 2008 seeking to commercialize oritavancin for the treatment of cSSSI.

About Targanta Therapeutics

Targanta Therapeutics Corporation is a privately held biopharmaceutical company focused on developing and commercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic, for which Targanta intends to seek U.S. regulatory approval in early 2008, as well as a number of antibacterial agents in pre-clinical development. The company has operations in Cambridge, MA, Indianapolis, IN, Montreal, Quebec, Canada and Toronto, Ontario, Canada. For further information about Targanta, visit the company's website at http://www.targanta.com.

Disclaimer

All forward-looking statements and other information included in this press release are based on information available to Targanta as of the date hereof, and Targanta assumes no obligation to update any such forward-looking statements or information. Targanta's actual results could differ materially from those described in Targanta's forward-looking statements.


'/>"/>
SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition ... - 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics ... the growing market of deep learning solutions within the healthcare domain. ... emerged as a novel solution to generate relevant insights from medical ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and ... 2015 through 2022. Also, a six-year historic analysis is provided for these ...
(Date:3/24/2017)... March 23, 2017  Mirabilis Medical, a ... technology for non-invasive surgery, announced today CE Mark ... treatment of uterine fibroids throughout the European Union.  ... approval from the US Food and Drug Administration ... System in the United States.  The Mirabilis System ...
Breaking Medicine Technology:
(Date:3/25/2017)... Kennett Square, PA (PRWEB) , ... March 25, 2017 , ... ... one priority as a public relations partner. , All through the year, Garden ... stories and press releases, working with key influencers and pitching client’s key messages ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... , ... According to a new study by NCPA Senior Fellow John R. ... rules Congress has directed the CBO to follow. The CBO itself previously recognized Obamacare ... it estimates a reduction in employer-based coverage due to the GOP reform, which is ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, proudly presents her ... 9--24, 2017. This sacred and spiritual journey during the Summer Solstice will ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. She will ... The majority of cases litigated under ERISA involve claims for long-term disability benefits. ...
Breaking Medicine News(10 mins):